351 related articles for article (PubMed ID: 21827707)
1. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
[TBL] [Abstract][Full Text] [Related]
2. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
3. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
4. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
[TBL] [Abstract][Full Text] [Related]
5. Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.
Bae JM; Kim JH; Kwak Y; Lee DW; Cha Y; Wen X; Lee TH; Cho NY; Jeong SY; Park KJ; Han SW; Lee HS; Kim TY; Kang GH
Br J Cancer; 2017 Apr; 116(8):1012-1020. PubMed ID: 28278514
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
[TBL] [Abstract][Full Text] [Related]
7. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
8. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
10. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
[TBL] [Abstract][Full Text] [Related]
11. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
[TBL] [Abstract][Full Text] [Related]
12. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.
Kim JH; Shin SH; Kwon HJ; Cho NY; Kang GH
Virchows Arch; 2009 Dec; 455(6):485-94. PubMed ID: 19911194
[TBL] [Abstract][Full Text] [Related]
14. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.
Kim CH; Huh JW; Kim HR; Kim YJ
J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988
[TBL] [Abstract][Full Text] [Related]
15. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.
Bae JM; Kim JH; Cho NY; Kim TY; Kang GH
Br J Cancer; 2013 Aug; 109(4):1004-12. PubMed ID: 23900220
[TBL] [Abstract][Full Text] [Related]
17. CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer.
Chen KH; Lin LI; Tseng LH; Lin YL; Liau JY; Tsai JH; Liang JT; Lin BR; Cheng AL; Yeh KH
Oncology; 2019; 96(3):156-163. PubMed ID: 30540994
[TBL] [Abstract][Full Text] [Related]
18. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
20. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
Van Rijnsoever M; Elsaleh H; Joseph D; McCaul K; Iacopetta B
Clin Cancer Res; 2003 Aug; 9(8):2898-903. PubMed ID: 12912934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]